Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570265 | 0.86 | BUB1 (0.31) | BUB1 | |
| SCHEMBL6159950 | 0.76 | BUB1 (0.32) | BUB1 | |
| SCHEMBL4985066 | 0.72 | GAA (0.48) | — | |
| SCHEMBL1657244 | 0.72 | BUB1 (0.35) | BUB1 | |
| SCHEMBL1657246 | 0.72 | BUB1 (0.35) | BUB1 | |
| SCHEMBL2598644 | 0.72 | BUB1 (0.35) | BUB1 | |
| SCHEMBL5997867 | 0.72 | — | — | |
| SCHEMBL29599566 | 0.70 | PPM1D (0.33) | — | |
| SCHEMBL16516673 | 0.70 | PPM1D (0.33) | — | |
| SCHEMBL1657412 | 0.69 | CCR2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599898-B2 | Selected from the group consisting of breast, lung, non-small cell lung, osteolytic, colon and prostate | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK RAY (US) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | VHL, CAPRIN1, CAPN9 | BUB1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.